益气健脾口服液联合痰热清雾化吸入治疗慢性阻塞性肺疾病稳定期患者临床研究

详细信息    查看全文 | 推荐本文 |

英文篇名：Clinical efficacy of Yiqi Jianpi oral liquid combined with Tanreqing aerosol inhalation on COPD patients in stable stage 作者：戴红卫 英文作者：DAI Hong-wei;Shanghai Songjiang District Yueyang Street Health Service Center; 关键词：慢性阻塞性肺疾病(COPD) ; 益气健脾口服液 ; 痰热清 ; 雾化吸入 ; 肺功能 英文关键词：chronic obstructive pulmonary disease(COPD);;Yiqi Jianpi oral liquid;;Tanreqing;;aerosol inhalation;;lung function 中文刊名：GWHH 英文刊名：World Clinical Drugs 机构：上海市松江区岳阳街道卫生服务中心全科; 出版日期：2019-02-10 11:45 出版单位：世界临床药物 年：2019 期：v.40;No.325 语种：中文; 页：GWHH201901012 页数：5 CN：01 ISSN：31-1939/R 分类号：62-66

摘要

目的探讨益气健脾口服液联合痰热清雾化吸入改善慢性阻塞性肺疾病(COPD)稳定期患者的临床疗效和安全性。方法纳入我院2016年5月至2018年3月随访的COPD稳定期患者106例,采取随机数字表法将其分为观察组与对照组,对照组(n=53)常规西医治疗,观察组(n=53)在对照组基础上益气健脾口服液联合痰热清雾化吸入治疗,比较两组患者疗效、症状缓解时间、治疗前后中医证候积分、肺功能指标及6 min步行距离、圣乔治呼吸问卷(SGRQ)评分,并分析两组治疗不良反应发生情况。结果观察组患者治疗总有效率(98.11%)高于对照组(86.79%,P <0.05);观察组患者咳嗽、发热消失时间、肺功能恢复正常时间均短于对照组(P <0.01);两组患者治疗后中医证候积分、第1 s用力呼气量(FEV1)、第1 s用力呼吸气量占预计值百分比(FEV1%)及6 min步行距离、SGRQ评分均一定程度改善,且观察组改善优于对照组(P <0.05);观察组不良反应(1.89%)与对照组(3.77%)相当(P> 0.05)。结论益气健脾口服液联合痰热清雾化吸入可显著提升COPD稳定期患者临床疗效,促进患者肺部功能恢复,改善生活质量,不良反应少,值得推广应用。
        Objective To explore the clinical efficacy and safety of Yiqi Jianpi oral liquid combined with Tanreqing aerosol inhalation in the patients with chronic obstructive pulmonary disease(COPD).Methods A total of 106 cases of COPD patients in stable stage from May 2016 to March 2018 follow-up were selected and randomly divided into observation group and control group as 53 cases each.The control group was treated with routine western medicine,and the observation group was treated with additional Yiqi Jianpi oral liquid combined with Tanreqing aerosol inhalation on the basis of control group.The patients' curative effect,symptom relief time,traditional Chinese medicine(TCM) syndrome score,pulmonary function index and 6-minute walking distance,St.George's respiratory questionnaire(SGRQ) score were compared in two groups before and after treatment,and the occurrence of adverse reactions in two groups was analyzed.Results The total effective rate of the observation group(98.11 %) was higher than that of control group(86.79%,P<0.05).The cough,fever disappearance time and pulmonary function recovery time in observation group were shorter than those in control group(P<0.01).The scores of TCM syndromes,FEV1,FEV1%,6-minute walking distance and SGRQ scores in both two groups were improved,but these indicates in observation group were improved better than those in control group(P<0.05).The adverse reactions in observation group(1.89%) were similar to those in control group(3.77%,P>0.05).Conclusion Yiqi Jianpi oral liquid combined with Tanreqing aerosol inhalation can significantly improve the clinical efficacy of COPD patients in stable stage.

引文

[1]周丹阳,毛山.2017版慢性阻塞性肺疾病全球倡议更新解读[J].世界临床药物,2018,39(1):1-5.
    [2]赵华琴.无创正压通气在慢阻肺急性发作临床治疗中的应用[J].四川医学,2017,38(1):72-74.
    [3]王淑敏,马健,金亚明,等.射干麻黄汤加减联合信必可治疗哮喘-慢性阻塞性肺疾病重叠综合征急性发作期临床研究[J].南京中医药大学学报,2017,33(5):535-537.
    [4]邹卫兵,付小刚,李敏,等.小青龙汤联合西药治疗老年慢性阻塞性肺疾病发作期的临床疗效及免疫调节作用[J].中国老年学杂志,2017,37(3):638-639.
    [5]中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2013年修订版)[J].中华结核和呼吸杂志,2013,36(4):255-264.
    [6]周仲瑛.中医内科学[M].6版.北京:中国中医药出版社,2003:91-124.
    [7]柳涛,蔡柏蔷.慢性阻塞性肺疾病患者生活质量评估方法及其意义[J].中国呼吸与危重监护杂志,2003,2(4):196-197.
    [8]严萍,王真.益气健脾法对COPD中重度稳定期脾肺气虚型患者症状及运动耐能的影响[J].浙江中西医结合杂志,2016,26(10):909-911.
    [9]郝文东,王国芳,张彩莲,等.痰热清注射液治疗AECOPD合并肺炎的临床疗效[J].中成药,2017,39(11):2431-2433.
    [10]曾凡兰.痰热清联合抗生素治疗慢性阻塞性肺疾病急性加重期临床疗效与经济学研究[J].实用医院临床杂志,2017,14(4):171-173.
    [11]黄燕玲,罗光伟,毛先明,等.痰热清对慢性阻塞性肺疾病大鼠支气管上皮多药耐药相关蛋白1表达的影响[J].中国老年学杂志,2017,37(2):318-320.
    [12]杨文昊,舒慧敏,刘凤阁,等.痰热清联合沙美特罗替卡松治疗COPD的疗效及对血气指标的影响[J].现代中西医结合杂志,2017,26(5):505-507.
    [13]章潜.益气健脾颗粒对COPD稳定期患者肺功能指标的影响[J].浙江中医药大学学报,2014,38(5):575-577.